In HCC therapy, CTLA-4 inhibitors (e.g., Ipilimumab and Tremelimumab) have demonstrated the ability to enhance T cell proliferation and functional activity by blocking CTLA-4-mediated immunosuppressive signaling pathway. This evidence concerns the gene CTLA4 and hepatocellular carcinoma.